

Thomas Jefferson University Jefferson Digital Commons

Department of Medicine Posters

Department of Medicine

10-24-2021

A Rare Case of Acute Hepatitis C Causing Coagulopathy and Severe Transaminitis

Timothy Kuchera, MD Muyi Li, MD Corey O'Brien, MD

Follow this and additional works at: https://jdc.jefferson.edu/medposters

Part of the Internal Medicine Commons

Let us know how access to this document benefits you

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Posters by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.



A Rare Case of Acute Hepatitis C Causing Coagulopathy and Severe Transaminitis

Timothy Kuchera, MD¹, Muyi Li, MD², Corey O'Brien, MD³

- 1. Department of Hospital Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
- 2. Department of Gastroenterology and Hepatology, University of Washington Medical Center, Seattle, WA
 - 3. Department of Hospital Medicine, University of Washington Medical Center, Seattle, WA

INTRODUCTION

- Although Hepatitis C (HCV) is extremely common, diagnosis of acute HCV is as rare as it is typically asymptomatic.
- The following is an uncommon presentation of symptomatic acute HCV resulting in sepsis, transaminitis, jaundice, and coagulopathy.

CLINICAL COURSE

- 36-year-old man with past medical history of intravenous drug use presented with acute headache, chills and fever of 104.6°F
- 2 months (6 weeks, 4 days) prior to admission the patient was admitted to a neighboring medical center for unrelated trauma.
 - HCV antibody incidentally noted to be positive but HCV Quantitative PCR was undetectable at that time
 - Liver Function Tests (LFTs) were within normal limits
- Interim history was notable for chills and lethargy but without vision changes, neck stiffness or abdominal pain
- Physical exam: without jaundice, asterixis, or abdominal tenderness
- Abdominal ultrasound of RUQ showed slightly heterogenous appearance of liver concerning for hepatitis with doppler negative for portal or splenic vein thrombosis (Figure 1)
- Initial labs: Total Bilirubin 2.0 mg/dL, Direct Bilirubin 1.7 mg/dL, AST 176 IU/L, ALT 264 IU/L, alkaline phosphatase 304 IU/L, INR 1.26. On hospital days 3-5, liver enzymes peaked at the following values: Total Bilirubin: 8.2 mg/dL, Direct Bilirubin: 7.2 mg/dL, AST: 5455 IU/L, ALT: 3032 IU/L, ALP: 320 IU/L, INR 2.60 (Figure 2A and 2B)
- Serologic workup for cirrhosis and sepsis: Table 1 and Table 2
- The patient was again noted to have a positive HCV antibody but now had an HCV Quantitative PCR of 2.72 million
- This pattern with prior testing suggested acute HCV infection. The patient was given supportive treatment and clinically improved
- Prior to discharge his fevers resolved, LFTs down-trended, coagulopathy improved, and repeat HCV Quantitative PCR was 8140


IMAGING


Figure 1: Slightly heterogeneous appearance of liver and gallbladder wall thickening without other signs of acute cholecystitis concerning for hepatitis



LIVER FUNCTION DURING HOSPITALIZATION

Figure 2: AST/ALT and INR (A) and Total and Direct Bilirubin (B) over course of hospitalization





LABORATORY RESULTS

Table 1: Infectious Workup

| Lab | Value | Range |
|----------------------------------|--------------|---------------|
| Hepatitis A Antibody, Total | Nonreactive | |
| Hepatitis A IgM | Nonreactive | |
| Hepatitis B Surface Antibody | Reactive | |
| Hepatitis B Surface Antigen | Negative | |
| Hepatitis B Core IgM, IgG | Negative | |
| Hepatitis C Antibody | Positive | |
| Hepatitis C PCR | 2.72 Million | |
| Cytomegalovirus IgG, IgM | Negative | |
| Cytomegalovirus Quantitative PCR | Negative | |
| Epstein Barr Virus (EBV) VCA IgM | <= 36.00 | <= 36.00 U/mL |
| EBV VCA IgG | 69.40 | < 18.00 U/mL |
| EBV EBNA IgG | > 600.00 | < 18.00 U/mL |
| EBV PCR | Negative | |
| HSV 1 IgM, HSV 2 IgM | Negative | |
| HSV 1 and HSV 2 DNA PCR | Negative | |
| HIV Antigen/Antibody Combination | Non-reactive | |
| Varicella Zoster Virus PCR | Negative | |
| Lyme Antibody | Negative | |

DISCUSSION

- 20-33% of patients with acute HCV are symptomatic with disease onset occurring between 2 and 12 weeks (mean of 7 weeks)¹
- The constellation of serologies in this patient raise the possibility of new acute HCV infection (prior to outside hospitalization) or reinfection in the setting of active intravenous drug use
- The patient was scheduled with Hepatology but was lost to follow-up

Table 2: Inflammatory, Rheumatologic, and Toxic Workup

| | 3 , | • |
|-------------------------------|---|-----------------|
| Lab | Value | Range |
| Salicylates | <0.3 | 2.8-20.0 mg/dL |
| Urine Drug Screen | Positive for Fentanyl and Buprenorphine | |
| IgG | 706 | 723-1,685 mg/dL |
| IgA | 177 | 69-382 mg/dL |
| IgM | 119 | 40-230 mg/dL |
| Serum Ethanol | Negative | |
| Phosphatidylethanol | Not Detected | |
| Gamma-Glutamyl Transpeptidase | 212 | 6-24 IU/L |
| Acetaminophen | < 5 | <= 25.0 mcg/mL |
| Ferritin | 608 | 30-400 ng/mL |
| C-Reactive Protein | 6.60 | <= 0.80 mg/dL |
| Anti-Smooth Muscle Antibody | Negative | |
| Sedimentation Rate | 11 | 0 - 15 mm/hr |
| Ceruloplasmin | 47 | 18-36 mg/dL |
| Serum Copper | 157 | 70 - 175 mcg/dL |
| Factor V Activity | 129 | 50-150% |
| Fibrinogen | 320 | 170 - 460 mg/dL |
| Antinuclear Antibody | Negative | |
| Ammonia | 59 | 11-35 mmol/L |
| | | |

REFERENCES

[1] DynaMed. Acute Hepatitis C Infection. EBSCO Information Services. Accessed September 7, 2021. https://www.dynamed.com/condition/acute-hepatitis-c-infection

DISCLOSURES: The authors have no conflicts of interest to disclose.